GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth

GlaxoSmithKline execs touted their HIV growth drive this week, pointing to next-generation medications Triumeq and Tivicay as the fuel. But both drugs actually fell short of analyst forecasts—and that's thanks to archrival Gilead Sciences and its newly launched Biktarvy.